Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 73
Selected: 0
NCT IDTitle
NCT00060710CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00497224Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
NCT01299220Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
NCT00073489A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00950365Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
NCT00499655Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
NCT00532441Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
NCT01567384A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
NCT01010945Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT00254410FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
NCT00591123Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
NCT00304278Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00072631Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT01427205Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00373425A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
NCT01257594EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
NCT00294762Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00672243Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
NCT00042055CP-461 for the Treatment of Crohn's Disease
NCT00283803Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
NCT00166426Exisulind Versus Placebo After Surgical Removal of the Prostate
NCT00040183OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
NCT01006096Erlotinib for Treatment of Psoriasis
NCT01180959Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT00116896Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT01032070Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
NCT00140556Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
NCT00603356Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
NCT00513851Phase 1 Study of OSI-930 in Cancer Patients
NCT00036257Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
NCT00033241Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00073502Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
NCT00385996Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01174043Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
NCT01038856Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
NCT00570232UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
NCT00871923Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
NCT00036647OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00139620A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
NCT00036036Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00640978Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
NCT00826449Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
NCT00739063Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
NCT00392665Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
NCT00046800Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
NCT00116909A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT00609804Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
NCT00369512A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
NCT00036075Study Using CP-461 to Treat Advanced Prostate Cancer